25 /100
LOW RISK
Score updated Jul 13, 2026

BBIO — BridgeBio Pharma, Inc. Dilution Risk Tracker

Track BBIO dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BBIO — Get alerts when the score changes →

As of July 13, 2026, BridgeBio Pharma, Inc. (BBIO) has a DilutionWatch DilutionScore of 25/100, rated LOW dilution risk. BridgeBio Pharma, Inc. has a market capitalization of $12.98B, 195.86M shares outstanding, 466 institutional holders tracked. Key dilution vectors include approximately 14 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
22
💰 Cash Runway
40
📊 Float Risk
22
⚠️ Warrant Exposure
15
🔄Convertible Debt—

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for BBIO.
🔔 Track BBIO — Get forecast alerts →

💹 Market Data

Market Cap$12.98B
Shares Outstanding195.86M
Float152.72M
Cash$887.83M
Debt$3.65M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 11.1% shares (2026Q1 vs prior)
466 institutional holders · 241.39M shares
#1 JANUS HENDERSON GROUP PLC 26.36M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 15.52M shares
#3 BlackRock, Inc. 14.21M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest24.10M
Days to Cover4.5
% of Float15.8%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2023
xbrl XBRL WARRANT Dec 31, 2023
4 INSIDER TRANSACTION Apr 13, 2026
4 INSIDER TRANSACTION Mar 20, 2026
4 INSIDER TRANSACTION Mar 20, 2026
Full SEC filing analysis available with free account →

📰 Recent News

No recent news

📋 What This Means for BBIO Shareholders

BridgeBio Pharma, Inc. (BBIO) has a DilutionScore of 25/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 13, 2026.

Cash runway is a key watch item: BBIO has approximately 14 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for BBIO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for BBIO alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track BBIO Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BBIO — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

LBTYA LBTYK AER AIG BABA

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for BBIO
📊 BBIO FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 BBIO Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.